Alkem Expands Access to Semaglutide with New Pre-Filled Syringe Launch

Introducing a More Convenient Treatment Option 

Alkem Laboratories has strengthened its diabetes and obesity care portfolio with the launch of semaglutide in single-shot pre-filled syringes across multiple dose strengths. Priced from INR 350, the new offering is designed to make treatment more accessible and affordable for patients. The company noted that it is the first pharmaceutical manufacturer in India to introduce semaglutide in this ready-to-use syringe format, providing a convenient alternative for individuals requiring long-term therapy. 

Regulatory Approval Supports Market Expansion 

The launch follows approval from the Drugs Controller General of India (DCGI), allowing Alkem to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity. The therapy is intended to be used alongside a healthy diet and regular exercise. By securing regulatory clearance, the company has broadened the availability of semaglutide-based treatment options for patients and healthcare providers across the country. 

According to Towards Healthcare, the India injection devices market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.98 billion in 2026 to approximately USD 4.27 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. The market is witnessing robust expansion, driven by rising chronic disease prevalence, increasing adoption of self-injection technologies, growing healthcare awareness, and continuous advancements in drug delivery systems nationwide. 

Building on a Growing Semaglutide Portfolio 

This latest introduction builds on Alkem’s earlier launch of semaglutide in disposable and reusable injection pen formats in March 2026. The company has also received approval for semaglutide vials and plans to bring them to the market in the near future. With multiple delivery formats available, Alkem aims to address varying patient preferences and treatment requirements while improving overall therapy adherence. 

Supporting Better Management of Metabolic Disorders 

According to Dr. Vikas Gupta, Chief Executive Officer of Alkem, semaglutide has the potential to transform the management of metabolic disorders. He emphasized that expanding delivery options gives doctors and patients greater flexibility in choosing suitable treatments. As the burden of diabetes and obesity continues to rise in India, Alkem remains focused on improving patient access to innovative therapies and supporting better long-term health outcomes nationwide. 

According to Towards Healthcare, the India injection devices market is projected to experience significant growth due to increasing demand for biologics, an expanding diabetic population, supportive healthcare infrastructure development, and greater preference for convenient, accurate, and patient-friendly injection solutions.